SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]
SEC Accession No. 0000950142-04-000475
Filing Date
2004-02-17
Accepted
2004-02-17 16:32:24
Documents
3
Group Members
FRANK H. PEARLGEORGE SOROSPERSEUS BIOTECH FUND PARTNERS, LLCPERSEUS EC, L.L.C.PERSEUS-SOROS PARTNERS, LLCPERSEUS-SOROS PHARMACEUTICAL FUND, L.P.PERSEUSPUR, LLCSFM AH LLCSFM PARTICIPATION, L.P.SOROS FUND MANAGEMENT LLC

Document Format Files

Seq Description Document Type Size
1 AXCAN PHARM INC -- AMENDMENT NO. 2 sc13da2-axcan.txt SC 13D/A 45230
3 EXHIBIT 1 ex_1sc13da2-axcan.txt EX-99 6645
4 EXHIBIT 2 ex_2sc13da2-axcan.txt EX-24 2175
  Complete submission text file 0000950142-04-000475.txt   56670
Mailing Address C/O AKIN, GUMP, STRAUSS,HAUER,FELD, 399 PARK AVENUE NEW YORK NY 10022
Business Address 888 SEVENTH AVENUE 33RD FLOOR NEW YORK NY 10106 2128721054
SOROS FUND MANAGEMENT LLC (Filed by) CIK: 0001029160 (see all company filings)

IRS No.: 133914976 | State of Incorp.: DE | Fiscal Year End: 1231

Mailing Address 597 LAURIER BLVD MT ST CLAIR QUEBEC CANADA
Business Address 597 LAURIER BLVD MONT ST HILAIRE QUEBEC CANADA J3H 6C A8 00000 4504675138
AXCAN PHARMA INC (Subject) CIK: 0001116094 (see all company filings)

IRS No.: 000000000 | Fiscal Year End: 0930
Type: SC 13D/A | Act: 34 | File No.: 005-59291 | Film No.: 04609246
SIC: 5122 Wholesale-Drugs, Proprietaries & Druggists' Sundries